Adicet Bio, Inc. (ACET)

Market Cap	62.88M
Revenue (ttm)	n/a
Net Income (ttm)	-115.16M
Shares Out	43.07M
EPS (ttm)	-2.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	287,463
Open	1.54
Previous Close	1.53
Day's Range	1.45 - 1.58
52-Week Range	1.45 - 21.87
Beta	1.58
Analysts	Buy
Price Target	17.67 (+1,110.27%)
Earnings Date	Nov 7, 2023

About ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1947
• Employees: 132
• Stock Exchange: NASDAQ
• Ticker Symbol: ACET

Financial Performance

In 2022, Adicet Bio's revenue was $24.99 million, an increase of 156.83% compared to the previous year's $9.73 million. Losses were -$69.79 million, 12.6% more than in 2021.

Analyst Forecast

According to 7 analysts, the average rating for ACET stock is "Buy." The 12-month stock price forecast is $17.67, which is an increase of 1,110.27% from the latest price.

Price Target

$17.67

(1,110.27% upside)

Analyst Consensus: Buy